Pharmafile Logo

What Is the RDI-Lancet Commission for Rare Disease and What Will It Achieve?

December 23, 2025 |  

Christy Rohani-Montez, Medscape’s Rare Disease Education Lead recently spoke with Dr Lucy McKay, CEO, and Megan Pullein, Strategic Operations Officer from the UK-based charity Medics for Rare Disease (MfRD). We discussed their involvement in the recently formed RDI-Lancet Commission for Rare Diseases, a global initiative aimed at developing evidence-based recommendations to improve the lives of the 400 million people living with rare diseases worldwide.

lucy                           Picture1megan

Lucy McKay                                                  Megan Pullein
CEO                                                                Strategic Operations Officer
Medics for Rare Disease                            Medics for Rare Disease

Christy: It’s lovely to be speaking with one of our favourite partners in rare disease, Medics for Rare Disease! Lucy, and Megan, could you start by introducing yourselves, Medics for Rare Disease, and its mission?

Lucy: Absolutely, I’m Dr Lucy McKay, the CEO of Medics for Rare Disease, and our vision is simple: equitable healthcare for everyone. Our mission is to shape a medical profession that can provide timely diagnosis and excellent care to people living with rare diseases.

Megan: I’m Megan Pullein, and I’m the Strategic Operations Officer at Medics for Rare Disease. My primary role is to help manage our work with the RDI-Lancet Commission, specifically for Working Group 2, which Lucy Co-Chairs.

Christy: What are the Lancet Commissions, and what is the RDI-Lancet Commission for Rare Diseases?

Megan: The Lancet Commissions are in-depth research initiatives that tackle urgent and complex global health issues. They gather experts from around the world to collaborate on solutions, which are then published in the renowned medical journal. The vision for this specific commission is to make rare diseases visible globally, ensuring that every person is seen, heard, and cared for, no matter where they live. The goal is to produce actionable recommendations that any government can take and implement within their society.

Christy: I understand that the commission is divided into 5 working groups. What is the focus of each?

Lucy: Before breaking down the groups, it’s important to state the golden thread that runs through all of this: human rights. The entire commission is fundamentally about achieving equity for patients around the world.

Megan: That leads perfectly into Working Group 1, which is focused on visibility for human rights. This is the core of the commission. Working Group 2, which we are leading, focuses on visibility for social justice. These are the 2 overarching themes. The other groups are more specific: Group 3 is looking at data and metrics; Group 4 is tackling visibility within healthcare systems, particularly the diagnostic odyssey; and Group 5 is focused on clinical pathways and trials.

Christy: Where does the work for each group start, and where does it end?

Lucy: We’re working in 3 phases. For example, in Working Group 2, first is a comprehensive literature review to answer the question: is social justice being achieved for people living with rare disease? If so, how? And if not, why not?

The second phase is generating new evidence. We want to fill the gaps we find in the literature, especially from geographical and demographical sources that are currently missing. We have a lofty goal of trying to represent advocates from every UN-recognized country, starting with the places from which we hear no voices.

The final phase will be to consolidate this evidence into concrete recommendations.

Christy: What do you find most exciting about RDI-Lancet Commission?

Lucy: For The Lancet to even highlight Rare Disease is a major milestone in history. What excites me is that this project forces us to pull back to focus on the individual. We constantly have to ask, for example, How is this recommendation going to help someone in rural Chile? It moves the conversation beyond tech, molecules, and industry chatter. Tech doesn’t matter to people if they can’t access it or are being treated without the respect every human being deserves.

It allows us to establish a global standard of provision for the rare disease community and will help shape The World Health Organisation’s Global Action Plan for Rare Disease. We hope that in the future there will be greater standardisation and transparency in how nations care for rare diseases. This will empower the rare disease community to understand what they are entitled to, the barriers to access and to demand accountability.

Christy: Thank you so much Lucy and Megan, it’s exciting to see this research moving forward, and we’re all looking forward to seeing the forthcoming publications.

For more information on the RDI-Lancet Commission:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00211-9/abstract

About Medscape Education

Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses for physicians, nurses, and other healthcare professional

This content was provided by Medscape Education

Company Details

 Latest Content from  Medscape Education 

The Ripple Effect: Why Connection is the Heart of Healthcare Leadership

In the fast-paced environment of clinical medicine, it is easy to focus solely on data and outcomes. However, as Dr. Toyin Nwafor (Gilead Sciences) and Dr. Shirin Mazumder (University of...

Beyond the Nudge: Why Mentorship is the New Healthcare Currency

In the latest episode of Hear From Her, the conversation centers on a striking reality: women in healthcare often face a "confidence gap" that their male counterparts do not. While...

Three Symposia, Three Years of Fellows, One Mission: Medscape Oncology at ASCO 2026

Three symposia. A third year of Fellows. AI live on the booth floor. Medscape Oncology arrives at ASCO 2026 (Booth #10099) with another ambitious oncology program.

How Sweet It Is: Medscape at ADA 2026

The energy is building as we prepare to head to New Orleans, LA, for the annual scientific sessions of the American Diabetes Association from June 4-8. The Medscape Diabetes and...

Keep the Beat Going: Education and Impact at the European Society of Cardiology Heart Failure Congress 2026

Did you know? Over 320,000 learners have engaged with heart failure content on Medscape. With such an enthusiastic audience for our education, we’re thrilled to be joining cardiology professionals from...

The Power of Partnership in Respiratory Care

In the fast-paced world of modern medicine, success is often measured by the volume of tests and the precision of data. However, as Dr. Doreen Addrizzo-Harris and Dr. Martina Flammer...

Beyond the Linear Path: Leading with Your Full Self

Listen to the full episode here. In the latest episode of the Hear From Her podcast, Giulia Ghibellini (Teva Pharmaceuticals) and Professor Amanda Kirby (Do-IT Solutions) share how their experiences...

Medscape Earns 2026 ANCC NCPD Premier Award for the Second Time, Reaffirming Leadership in Healthcare Education

Medscape, the leading digital platform for clinicians around the globe, has earned the 2026 American Nurses Credentialing Center (ANCC) NCPD Premier Award. This prestigious designation was publicly announced at the...

Leading with Heart: Why Vulnerability is a Force Multiplier

In a world that often prizes "macho" decisiveness, Dr. Lobna Salem (CMO at Viatris) and Dr. Amrit Ray (Board Chairman and former Pfizer executive) are advocating for a more human...

Cardiology Education in the Age of AI: Join Medscape at ACC 2026

  As medical knowledge now doubles every 73 days, the challenge for cardiology clinicians has shifted from finding information to mastering precision. At the American College of Cardiology (ACC) 65th...